Here are three big things on investors’ minds as earnings season kicks off.
It looks like Novartis let a big one get away.
Results from a Phase 3 clinical trial, BEACON CRC, evaluating Array BioPharma's (ARRY) BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) + Eli Lilly's ERBITUX
Tuesday, June 25, 2019For the second consecutive day, we see another major acquisition during the pre-market period. Yesterday was the Gaming industry’s buyout of Caesars...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Sell||Buy||Buy|
|Technical Indicators||Strong Sell||Strong Sell||BUY||Neutral||BUY|
|Summary||Strong Sell||Strong Sell||Neutral||Neutral||Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Engulfing Bearish||1M||3||Apr 19|
|Evening Doji Star||1M||12||Jul 18|
|Falling Three Methods||1M||12||Jul 18|
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.